4//SEC Filing
Ho Carole 4
Accession 0001714899-25-000176
CIK 0001714899other
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 8:33 PM ET
Size
8.7 KB
Accession
0001714899-25-000176
Insider Transaction Report
Form 4
Ho Carole
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-08-12$13.58/sh−2,937$39,884→ 217,391 total - Sale
Common Stock
2025-08-13$14.64/sh−806$11,800→ 216,585 total
Holdings
- 25,000(indirect: See footnote)
Common Stock
- 183,219(indirect: See footnote)
Common Stock
Footnotes (6)
- [F1]Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- [F2]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Includes 128,405 Unvested RSUs.
- [F4]The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024.
- [F5]The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
- [F6]The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
Documents
Issuer
Denali Therapeutics Inc.
CIK 0001714899
Entity typeother
Related Parties
1- filerCIK 0001724605
Filing Metadata
- Form type
- 4
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 8:33 PM ET
- Size
- 8.7 KB